Gazyva
FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for ...
MARCH 8, 2024
FDA Approves Imbruvica With Gazyva for First-Line CLL Treatment
The labeling for ibrutinib (Imbruvica, Pharmacyclics/Janssen) has been expanded to include use with obinutuzumab ...
FEBRUARY 4, 2019
FDA Approves Gazyva for Previously Untreated Advanced FL
The FDA granted regular approval to obinutuzumab (Gazyva, Genentech) for use in treatment-naive adults with stage ...
NOVEMBER 21, 2017
Load more